biOasis Technologies, Inc. (BIOAF)
0.0000
0.00 (0.00%)
USD |
OTCM |
Jan 14, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0001M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.50% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| biOasis Technologies, Inc. operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in New Haven, CT. |
| URL | http://www.bioasis.us |
| Investor Relations URL | http://www.bioasis.ca/market-profile/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| biOasis Technologies, Inc. operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in New Haven, CT. |
| URL | http://www.bioasis.us |
| Investor Relations URL | http://www.bioasis.ca/market-profile/ |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |